Angelini Ventures opens Singapore office to boost biotech growth.

Angelini Ventures has established its first Asian foothold with a new office in Singapore’s Central Business District, marking a strategic shift for the Rome‑based corporate investor into the region’s life sciences market. The move positions the firm as an on‑the‑ground partner for startups and institutional players across biotech and healthtech, reinforcing Singapore’s role as a gateway between Asia and Europe.

The office will host the fund’s data platform, the Angelini Ventures Intelligence Hub, and assemble local teams of researchers, clinicians and industry professionals to accelerate deal sourcing and translational projects. The venture arm manages an evergreen pool of capital totalling €300 million and has deployed roughly €125 million across 22 startups since its 2022 launch — a footprint the firm says it intends to expand in Asia.

Angelini’s entry into Singapore follows its first regional investment in the Singapore‑based biotech Nuevocor, where the firm co‑led a US$45 million Series B in 2025. That transaction is presented internally as a catalyst for deeper engagement in gene therapy and cardiovascular R&D, areas that are increasingly moving from discovery labs into clinical development across Asia.

Leadership for the new office will be provided by Elia Stupka, a life sciences executive with more than two decades of academic and industry experience in genomics and translational research, backed by a global network of advisors. CEO Sergio Marullo di Condojanni framed the expansion as part of a broader corporate strategy that links Angelini’s pharmaceutical and consumer health activities with venture investing to accelerate patient‑centric innovation.

Beyond presence, Angelini Ventures has formalised collaborations with ecosystem anchors. A partnership with Enterprise Singapore will launch a bespoke venture readiness programme called Espresso Lab, offering mentorship, market‑entry support and tailored business development for biomedical startups aiming to scale into European markets. Separately, an MoU with AI Singapore will drive joint initiatives to commercialise AI tools for diagnostics, drug discovery and clinical workflows.